Kintegral Advisory LLC Sells 1,582 Shares of Illumina, Inc. (NASDAQ:ILMN)

Kintegral Advisory LLC cut its holdings in Illumina, Inc. (NASDAQ:ILMN) by 4.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,957 shares of the life sciences company’s stock after selling 1,582 shares during the period. Kintegral Advisory LLC’s holdings in Illumina were worth $4,538,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Versant Capital Management Inc grew its holdings in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 146 shares in the last quarter. Golden State Wealth Management LLC bought a new position in shares of Illumina in the fourth quarter valued at approximately $32,000. TD Private Client Wealth LLC grew its holdings in shares of Illumina by 58.5% in the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after acquiring an additional 141 shares in the last quarter. V Square Quantitative Management LLC grew its holdings in shares of Illumina by 50.6% in the fourth quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company’s stock valued at $52,000 after acquiring an additional 132 shares in the last quarter. Finally, Private Trust Co. NA grew its holdings in shares of Illumina by 81.2% in the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after acquiring an additional 212 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Trading Down 3.1 %

Shares of ILMN stock opened at $94.20 on Friday. The business’s fifty day moving average is $127.98 and its 200 day moving average is $134.01. Illumina, Inc. has a 52-week low of $93.50 and a 52-week high of $156.66. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities research analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ILMN. Morgan Stanley reduced their price objective on Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a report on Tuesday, February 11th. Canaccord Genuity Group reduced their price objective on Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a report on Friday, February 7th. Guggenheim reduced their price objective on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a report on Friday, February 7th. Robert W. Baird increased their price objective on Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Finally, Citigroup lowered Illumina from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $190.00 to $165.00 in a report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $159.45.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.